Creative Planning Mirati Therapeutics, Inc. Transaction History

Creative Planning

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$41.99 - $62.38 $144,487 - $214,649	3,441 Added 2294.0%	3,591 $210,000
Q3 2023 Nov 16, 2023	BUY	$27.8 - $45.35 $4,170 - $6,802	150 New	150 $6,000
Q1 2022 May 16, 2022	SELL	$75.82 - $150.97 $117,824 - $234,607	-1,554 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$132.01 - $190.29 $924 - $1,332	-7 Reduced 0.45%	1,554 $228,000
Q3 2021 Nov 10, 2021	BUY	$132.13 - $177.45 $924 - $1,242	7 Added 0.45%	1,561 $276,000
Q2 2021 Aug 04, 2021	SELL	$144.0 - $179.73 $288,000 - $359,460	-2,000 Reduced 56.27%	1,554 $251,000
Q1 2021 Apr 30, 2021	BUY	$158.92 - $221.61 $22,089 - $30,803	139 Added 4.07%	3,554 $609,000
Q3 2020 Nov 05, 2020	BUY	$113.26 - $167.27 $1,698 - $2,509	15 Added 0.44%	3,415 $567,000
Q2 2020 Jul 23, 2020	BUY	$72.01 - $120.39 $18,002 - $30,097	250 Added 7.94%	3,400 $388,000
Q1 2020 May 05, 2020	SELL	$69.78 - $116.21 $263,768 - $439,273	-3,780 Reduced 54.55%	3,150 $242,000
Q4 2019 Jan 30, 2020	BUY	$70.76 - $128.86 $267,472 - $487,090	3,780 Added 120.0%	6,930 $893,000
Q1 2019 Apr 24, 2019	BUY	$43.65 - $78.95 $137,497 - $248,692	3,150 New	3,150 $231,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

Stay updated on Creative Planning with notifications on news.